Klára Brožová

Dr. Klára Brožová


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
DSDaphne H. Schoenmakers
Daphne H. Schoenmakers
MAMarije A.B.C. Asbreuk
Marije A.B.C. Asbreuk
TMTamara Martin
Tamara Martin
MDMareen Datema
Mareen Datema
SBShanice Beerepoot
Shanice Beerepoot
NWNicole Wolf
Nicole Wolf
Treatment decisions in metachromatic leukodystrophy (MLD), a rare life-threatening neurological disease, are challenging. Hematopoietic stem cell transplantation or autologous stem-cell-based gene therapy can be life-changing but come with uncertainties, risks, and high costs. To address this, the international MLD treatment eligibility panel was established in collaboration with the European Reference Network on Rare Neurological Diseases. The panel reviews and discusses individual MLD cases and provides consensus-based recommendations on whether to treat and which treatment modality. The goal is to streamline international care and treatment counseling by providing uncomplicated access to expert opinion. The panel operates according to a published standard operating procedure and was evaluated between September 2021-2024. Case data were recorded in a Castor EDC-based system and, with consent, included in the MLD Initiative (MLDi) patient registry. Physicians' experiences were assessed via EUsurvey, and patients' feedback was collected through an MLDi registry survey. The panel discussed 43 cases, recommending treatment in 20, abstaining in 19, and reaching no consensus in 4. Open questions regarding cognitive function and lack of outcome data caused challenges in treatment recommendations in late-onset MLD patients. All treatment recommendations were followed. Physicians reported positive experiences with the panel. The MLD treatment eligibility panel demonstrates how international expert advice can be streamlined across Europe for a rare disease like MLD, where disease-specific guidelines are still in development. By balancing complex clinical, social, and ethical parameters, the panel aids in encouraging appropriate use of innovative and costly therapies and guarantees accessibility to expert advice irrespective of country of origin.

6 April 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
JUJana Urbanová
Jana Urbanová
BFBrian M. Frier
Brian M. Frier
ATArian Taniwall
Arian Taniwall
KBKlára Brožová
Klára Brožová
JMJana Malinovská
Jana Malinovská
JBJan Broz
Jan Broz

1 September 2019 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
KBKlára Brožová
Klára Brožová
HKHana Krásničanová
Hana Krásničanová
RRRobert Rusina
Robert Rusina

1 January 2021
Verified
Journal Article
Closed access
KBKlára Brožová
Klára Brožová
AHAnna Holubova
Anna Holubova
PBPetra Borilova
Petra Borilova
MBMarek Brabec
Marek Brabec
PKPavel Kohout
Pavel Kohout
JBJan Broz
Jan Broz

4 July 2023 in Epilepsia Open
Verified
Journal Article
Open access
KBKlára Brožová
Klára Brožová
Juraj MichalecJuraj Michalec
Juraj Michalec
MBMarek Brabec
Marek Brabec
PBPetra Bořilová
Petra Bořilová
PKPavel Kohout
Pavel Kohout
JBJan Broz
Jan Broz
Objective: The ketogenic diet (KD) is a diet low in carbohydrates and rich in fats which has long been used to treat refractory epilepsy. The metabolic changes related to the KD may increase the risk of hypoglycemia, especially during the first days. The study focused on the impact of KD initiation on glycemia in non‐diabetic patients with refractory epilepsy.Methods: The subjects were 10 pediatric patients (6 boys, mean age 6.1 ± 2.4 years), treated for intractable epilepsy. Blinded continuous glucose monitoring system (CGM) Dexcom G4 was used. Patients started on their regular diet in the first 36 hours of monitoring, followed by an increase in lipids intake and a gradual reduction of carbohydrates (relations 1:1; 2:1; 3:1; 3.5:1). We analyzed changes in glycemia during fat: nonfat ratio changes using a generalized linear model.Results: The mean monitored time per person was 6 days, 10 hours and 44 minutes. The mean ± SD glycemia for the regular diet was 4.84 ± 0.20 mmol/L, for the carbohydrates/fat ratio of 1:1 it was 4.03 ± 0.16, for the ratio of 2:1 it was 3.57 ± 0.10, for the ratio 3:1 it was 3.39 ± 0.13 and for the final ratio of 3.5:1 it was 2.79 ± 0.06 mmol/L (P < 0.001). The portions of time spent in glycemia ≤3.5 mmol/L (≤2.5 mmol/L respectively) were: on the normal diet 0.88% (0.31%) of the monitored period, during 1:1 KD ratio 1.92% (0.95%), during 2:1 ratio 3.18% (1.02%), and during 3:1 and 3.5:1 ratios 13.64% (2.36%) of the monitored time (P < 0.05).Significance: Continuous glucose monitoring system shows the dynamic of glucose concentration in ketogenic diet treatment initiation. It may be a useful tool to control the effects of this diet on glucose metabolism, especially in hypoglycemia detection.

30 April 2024 in Česká a slovenská neurologie a neurochirurgie
Verified
Journal Article
Closed access
JMJuraj Michalec
Juraj Michalec
KBKlára Brožová
Klára Brožová
JOJakub Otáhal
Jakub Otáhal
SKSvatava Krejčová
Svatava Krejčová
JUJana Urbanová
Jana Urbanová
JBJan Brož
Jan Brož